On March 18, 2021 Acacia Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, reported that it will report its results for the full year 2020 and provide an update on progress with the commercialization of BARHEMSYS and BYFAVO on Monday, 29 March 2021 at 07.00 CEST (Press release, Acacia Pharma, MAR 18, 2021, View Source [SID1234576841]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A presentation by Acacia Pharma’s senior management team will be webcast live the same day at 14.30 CEST (08.30 EST).

The webcast can be accessed from www.acaciapharma.com and a recording will be available after the event.

The results report and presentation will be available at www.acaciapharma.com in the Investors section from 07.00 CEST the same day.